Kedokteran & Kesehatan editorial
Open AccessOA2024
Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial
In the TRAIN trial across 72 ICUs in 22 countries, liberal red blood cell transfusion (threshold <9 g/dL) led to a 10% absolute reduction in unfavorable neurological outcomes at 180 days compared to a restrictive strategy (<7 g/dL) in patients with acute brain injury and anemia.
F. Taccone; Carla Rynkowski Bittencourt; Kirsten Møller; Piet Lormans; Manuel Quintana-Díaz; A. Caricato; Marco Antonio Cardoso Ferreira; R. Badenes; Pedro Kurtz; C. Søndergaard; Kirsten Colpaert; Letícia Petterson; Hervé Quintard; R. Cinotti; Elisa Gouvêa Bogossian; C. Righy; Serena Silva; E. Roman-Pognuz; Catherine Vandewaeter; Daniel Lemke; Olivier Huet; A. Mahmoodpoor; Aaron Blandino Ortiz; M. van der Jagt; R. Chabanne; W. Videtta; P. Bouzat; J. Vincent· Journal of the American Medical Association (JAMA)· 2024· DOI 10.1001/jama.2024.20424
The core problem
Blood transfusions are frequently administered to patients with acute brain injury, yet the optimal hemoglobin threshold for triggering transfusion remains uncertain. Anemia is common in this population and may exacerbate secondary brain injury by reducing oxygen delivery. However, transfusions carry risks, including infection, transfusion-related reactions, and potential cerebral ischemia. The TRAIN (Transfusion Strategies in Acute Brain Injured Patients) trial was designed to determine whether a liberal or restrictive hemoglobin threshold for red blood cell transfusion improves neurological outcomes in patients with acute brain injury. The study addresses a critical gap in evidence, as previous trials in general critical care populations have yielded conflicting results, and patients with brain injury are often excluded from such trials due to concerns about cerebral oxygenation.
Innovation
The TRAIN trial was a multicenter, phase 3, parallel-group, investigator-initiated, pragmatic, open-label randomized clinical trial conducted in 72 intensive care units across 22 countries. Eligible patients had traumatic brain injury, aneurysmal subarachnoid hemorrhage, or intracerebral hemorrhage; hemoglobin values below 9 g/dL within the first 10 days after injury; and an expected ICU stay of at least 72 hours. Enrollment occurred between September 1, 2017, and December 31, 2022, with the last day of follow-up on June 30, 2023. A total of 850 patients were randomly assigned to either a liberal transfusion strategy (transfusion triggered by hemoglobin <9 g/dL; n=408) or a restrictive strategy (transfusion triggered by hemoglobin <7 g/dL; n=442) over a 28-day period. The primary outcome was the occurrence of an unfavorable neurological outcome, defined as a Glasgow Outcome Scale Extended (GOSE) score between 1 and 5, at 180 days following randomization. There were 14 prespecified serious adverse events, including cerebral ischemia after randomization. The trial was registered with ClinicalTrials.gov (NCT02968654).
Introduction
Blood transfusions are frequently administered to patients with acute brain injury, yet the optimal hemoglobin threshold for triggering transfusion remains uncertain. Anemia is common in this population and may exacerbate secondary brain injury by reducing oxygen delivery. However, transfusions carry risks, including infection, transfusion-related reactions, and potential cerebral ischemia. The TRAIN (Transfusion Strategies in Acute Brain Injured Patients) trial was designed to determine whether a liberal or restrictive hemoglobin threshold for red blood cell transfusion improves neurological outcomes in patients with acute brain injury. The study addresses a critical gap in evidence, as previous trials in general critical care populations have yielded conflicting results, and patients with brain injury are often excluded from such trials due to concerns about cerebral oxygenation.
Why it matters
The TRAIN trial demonstrates that in patients with acute brain injury and anemia, a liberal transfusion strategy targeting a hemoglobin threshold of 9 g/dL significantly reduces the risk of unfavorable neurological outcomes at 180 days compared to a restrictive strategy targeting 7 g/dL. The absolute risk reduction of 10% is clinically meaningful, with a number needed to treat of 10 to prevent one unfavorable outcome. The findings also show a lower incidence of cerebral ischemic events in the liberal group, suggesting that maintaining higher hemoglobin levels may improve cerebral oxygen delivery and mitigate secondary injury. These results contrast with trials in general critically ill populations, where restrictive strategies have often been non-inferior. The consistency of the effect across subgroups strengthens the generalizability of the findings. However, the open-label design and the pragmatic nature of the trial may introduce some bias, though the objective primary outcome and adjudicated events mitigate this concern. The trial's limitations include the lack of blinding and the potential for practice variations across centers. Nonetheless, the results support the use of a liberal transfusion threshold in this vulnerable population. The authors conclude that patients with acute brain injury and anemia randomized to a liberal transfusion strategy were less likely to have an unfavorable neurological outcome than those randomized to a restrictive strategy. These findings may inform clinical practice and guidelines for transfusion in neurocritical care.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member content…